poisar

Stocks · News reference

Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ADCT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — ADC Therapeutics SA (ADCT)

    Filed: 2026-10-13 AccNo: 0000950103-26-015465 Size: 808 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

    ADCT